CA2561733A1 - Pegylated ion channel modulating compounds - Google Patents

Pegylated ion channel modulating compounds Download PDF

Info

Publication number
CA2561733A1
CA2561733A1 CA002561733A CA2561733A CA2561733A1 CA 2561733 A1 CA2561733 A1 CA 2561733A1 CA 002561733 A CA002561733 A CA 002561733A CA 2561733 A CA2561733 A CA 2561733A CA 2561733 A1 CA2561733 A1 CA 2561733A1
Authority
CA
Canada
Prior art keywords
compound
hydrogen
formula
c6alkyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002561733A
Other languages
English (en)
French (fr)
Inventor
Elizabeth L. S. Cheu
Lewis Siu Leung Choi
Doug Ta Huang Chou
Allen W. Davidoff
Alan M. Ezrin
Grace Jung
Bertrand M. C. Plouvier
Aregahegn Yifru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiome Pharma Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2561733A1 publication Critical patent/CA2561733A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/04—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines without replacement of the other oxygen atom of the carboxyl group, e.g. imino-ethers
    • C07C257/06—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines without replacement of the other oxygen atom of the carboxyl group, e.g. imino-ethers having carbon atoms of imino-carboxyl groups bound to hydrogen atoms, to acyclic carbon atoms, or to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002561733A 2004-04-01 2005-03-31 Pegylated ion channel modulating compounds Abandoned CA2561733A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55940504P 2004-04-01 2004-04-01
US58699204P 2004-07-08 2004-07-08
US60/586,992 2004-07-08
PCT/US2005/011124 WO2005094897A2 (en) 2004-04-01 2005-03-31 Pegylated ion channel modulating compounds
US60/559,405 2005-04-01

Publications (1)

Publication Number Publication Date
CA2561733A1 true CA2561733A1 (en) 2005-10-13

Family

ID=34972985

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002561733A Abandoned CA2561733A1 (en) 2004-04-01 2005-03-31 Pegylated ion channel modulating compounds

Country Status (6)

Country Link
US (2) US7786119B2 (https=)
EP (1) EP1729814A2 (https=)
JP (4) JP4991037B2 (https=)
CA (1) CA2561733A1 (https=)
MX (1) MXPA06011420A (https=)
WO (1) WO2005094897A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090041841A1 (en) * 2003-05-02 2009-02-12 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
US7705036B2 (en) * 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
US7754897B2 (en) 2005-06-15 2010-07-13 Cardiome Pharma Corp. Synthetic processes for the preparation of aminocyclohexyl ether compounds
WO2005097087A2 (en) * 2004-04-01 2005-10-20 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
MXPA06011419A (es) 2004-04-01 2007-04-20 Cardiome Pharma Corp Profarmacos de compuestos moduladores de canales ionicos y usos de los mismos.
JP4991037B2 (ja) * 2004-04-01 2012-08-01 カーディオム ファーマ コーポレイション イオンチャネル調節化合物を含む薬物結合体
EP1828099B1 (en) 2004-11-18 2020-01-22 Correvio International Sàrl Synthetic process for aminocyclohexyl ether compounds
JP2007131597A (ja) * 2005-11-11 2007-05-31 Toray Fine Chemicals Co Ltd ベンジルオキシピロリジン誘導体の製造方法
JP5004067B2 (ja) * 2005-10-31 2012-08-22 東レ・ファインケミカル株式会社 ベンジルオキシ含窒素環状化合物の製造法
JP5004073B2 (ja) * 2006-06-13 2012-08-22 東レ・ファインケミカル株式会社 光学活性ベンジルオキシピロリジン誘導体塩酸塩粉体及びその製造法
CA2627502C (en) * 2005-10-31 2014-04-01 Toray Fine Chemicals Co., Ltd. Process for production of benzyloxypyrrolidine derivative, and process for production of hydrochloride salt powder of optically active benzyloxypyrrolidine derivative
WO2008112287A1 (en) 2007-03-12 2008-09-18 Nektar Therapeutics Oligomer-beta blocker conjugates
US8748648B2 (en) 2007-09-06 2014-06-10 Nektar Therapeutics Oligomer-calcium channel blocker conjugates
WO2009089053A1 (en) * 2008-01-11 2009-07-16 Nektar Therapeutics Al, Corporation Oligomer-guanidine class conjugates
JP5773877B2 (ja) * 2008-10-22 2015-09-02 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療する化合物
US20120010144A1 (en) * 2009-04-03 2012-01-12 Ragheb Assaly Peg-albumin composition having at least one protected thiol region as a platform for medications
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US9974759B2 (en) 2013-05-31 2018-05-22 Indiana University Research And Technology Corporation Beta 2 adrenoceptor antagonists for treating orthostatic hypotension

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684728A (en) * 1979-01-12 1987-08-04 Bayer Aktiengesellschaft Solubilizing biologically active compounds with reactive hydrogen atoms
IT1145362B (it) 1980-03-06 1986-11-05 Sigma Tau Ind Farmaceuti Classe di acil-derivati della carnitina procedimento per la loro preparazione e loro uso terapeutico
US5160734A (en) * 1987-11-25 1992-11-03 American Cyanamid Company Sustained release delivery system for substituted dihydropyridine calcium channel blockers
ATE76292T1 (de) * 1987-11-25 1992-06-15 American Cyanamid Co System fuer die verzoegerte (kontrollierte) freisetzung von substituierten dihydropyridincalciumantagonisten.
US20030186869A1 (en) 1990-05-14 2003-10-02 George Poiani Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
US6517824B1 (en) 1990-05-14 2003-02-11 University Of Medicine & Denistry Of New Jersey Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5244889A (en) 1991-11-26 1993-09-14 Ciba-Geigy Corporation Certain macrocyclic lactam derivatives
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US5298492A (en) 1992-08-04 1994-03-29 Schering Corporation Diamino acid derivatives as antihypertensives
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
JP3563738B2 (ja) 1993-06-11 2004-09-08 エーザイ株式会社 アミノ酸誘導体
DE69429524T2 (de) * 1993-09-24 2002-08-08 The University Of British Columbia, Vancouver Aminocyclohexylester und ihre anwendung
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
DE69735057T2 (de) * 1996-03-12 2006-08-31 PG-TXL Co., L.P., Houston Wasserlösliche paclitaxel-prodrogen
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
AU5194998A (en) 1996-11-01 1998-05-29 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and uses therefor
EP0884325A1 (en) 1997-04-24 1998-12-16 Akzo Nobel N.V. Thrombin inhibitors containing a peptidyl heterocycle
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
EP0991660B8 (en) 1997-10-08 2006-04-05 Isotechnika,Inc. DEUTERATED and undeuterated CYCLOSPORINE ANALOGS AND THEIR USE AS IMMUNOMODULATING AGENTS
CA2326777C (en) 1998-04-01 2011-12-20 Nortran Pharmaceuticals Inc. Aminocyclohexyl ether compounds and uses thereof
CA2319142A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel therapeutic agents for membrane transporters
EP1143896B1 (en) * 1998-10-20 2006-12-13 The University of North Carolina at Chapel Hill Methods of hydrating the nasal mucosal surface
WO2000047547A2 (en) * 1999-02-12 2000-08-17 Nortran Pharmaceuticals Inc. Cycloalkyl amine compounds and uses thereof
WO2000066110A1 (en) 1999-04-29 2000-11-09 Merck Patent Gmbh Glycine cleavage system inhibitors as potential antipsychotics
CA2311483A1 (en) * 2000-06-12 2001-12-12 Gregory N Beatch IMIDAZO [1,2-A] PYRIDINIC ETHERS AND USES THEREOF
WO2002028412A1 (en) 2000-10-05 2002-04-11 Zealand Pharmaceuticals A/S Novel use of peptide
CA2422916A1 (en) * 2000-09-26 2002-04-04 The University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
JP2002105067A (ja) 2000-09-28 2002-04-10 Teijin Ltd ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物
US7057053B2 (en) * 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7524879B2 (en) * 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US6631745B2 (en) 2001-07-02 2003-10-14 Fmc Technologies, Inc. Riser pull-in method and apparatus
US6623729B2 (en) 2001-07-09 2003-09-23 Korea Advanced Institute Of Science And Technology Process for preparing sustained release micelle employing conjugate of anticancer drug and biodegradable polymer
JP2005501052A (ja) 2001-07-31 2005-01-13 イムノメディクス， インコーポレイテッド ポリマー送達系
JP2003113084A (ja) 2001-10-02 2003-04-18 Mitsubishi Pharma Corp 肺高血圧症の治療及び／または予防薬
IL147953A (en) 2002-02-01 2008-04-13 Meir Bialer Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl-
TW200407310A (en) 2002-06-07 2004-05-16 Glaxo Group Ltd Compounds
BR0312176A (pt) * 2002-06-21 2005-04-05 Suven Life Sciences Ltd Composto, composição farmaceutica, uso de um composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso, processo para a preparação de um composto, novo intermediario e processo para a preparação de um novo intermediario
PL374781A1 (en) * 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
WO2004014973A2 (en) 2002-08-13 2004-02-19 Sirus Pharmaceuticals Ltd Biodegradable polymer
WO2004082585A2 (en) 2003-03-20 2004-09-30 Sirus Pharmaceuticals Ltd Water-soluble conjugates of phenytoin
WO2004098525A2 (en) 2003-05-02 2004-11-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
CA2524323C (en) 2003-05-02 2012-05-15 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
KR100495009B1 (ko) 2003-07-02 2005-06-14 삼성전자주식회사 화상형성 장치의 전사벨트 텐션 자동 인가 장치
WO2005018635A2 (en) 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
WO2005079861A2 (en) * 2004-02-13 2005-09-01 Safeway Investments Ltd. Polymeric water soluble prodrugs
MXPA06011419A (es) * 2004-04-01 2007-04-20 Cardiome Pharma Corp Profarmacos de compuestos moduladores de canales ionicos y usos de los mismos.
WO2005097203A2 (en) 2004-04-01 2005-10-20 Cardiome Pharma Corp. Serum protein conjugates of ion channel modulating compounds and uses thereof
US7754897B2 (en) 2005-06-15 2010-07-13 Cardiome Pharma Corp. Synthetic processes for the preparation of aminocyclohexyl ether compounds
JP4991037B2 (ja) * 2004-04-01 2012-08-01 カーディオム ファーマ コーポレイション イオンチャネル調節化合物を含む薬物結合体
US7705036B2 (en) * 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
US7845611B1 (en) * 2007-11-16 2010-12-07 Sholander Alfred M Door operated page turner device, system and method for books

Also Published As

Publication number Publication date
JP2007531766A (ja) 2007-11-08
JP4991037B2 (ja) 2012-08-01
JP2007531731A (ja) 2007-11-08
JP2008179653A (ja) 2008-08-07
JP2008214353A (ja) 2008-09-18
US20080021005A1 (en) 2008-01-24
WO2005094897A2 (en) 2005-10-13
US7786119B2 (en) 2010-08-31
JP4954864B2 (ja) 2012-06-20
WO2005094897A3 (en) 2006-06-22
MXPA06011420A (es) 2007-04-20
US20100273724A1 (en) 2010-10-28
EP1729814A2 (en) 2006-12-13

Similar Documents

Publication Publication Date Title
US20100273724A1 (en) Pegylated ion channel modulating compounds
AU2011201015B2 (en) Aminocyclohexyl ether compounds and uses thereof
EA022384B1 (ru) Ингибиторы вируса гепатита c
HUE028373T2 (en) Arylalkylamines and processes for their preparation
TW201034690A (en) Technetium-and rhenium-bis (heteroaryl) complexes and methods of use thereof for inhibiting PSMA
KR101520302B1 (ko) 돌라스타틴 10 유도체, 그의 제조방법 및 그를 포함하는 항암제 조성물
KR20230104191A (ko) 질환 치료를 위한 이환식 화합물 및 그 용도
CN114181277A (zh) 一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
KR20230106637A (ko) 빈혈 및 암 치료용 vhl 억제제로서의 1-(2-(4-시클로프로필-1h-1,2,3-트리아졸-1-일)아세틸)-4-히드록시-n-(벤질)피롤리딘 e-2-카르복사미드 유도체
KR20220035204A (ko) Vmat2 억제제 및 이의 제조 방법 및 용도
AU2020229920B2 (en) Acryloyl-containing nuclear transport regulator and uses thereof
US8058304B2 (en) Merged ion channel modulating compounds and uses thereof
US20110306649A1 (en) Prodrugs of ion channel modulating compounds and uses thereof
WO2005097203A2 (en) Serum protein conjugates of ion channel modulating compounds and uses thereof
CN102741227B (zh) 芳基苄基胺化合物
JP7714224B2 (ja) ボロノフェニルアラニンアミド誘導体
RU2838463C2 (ru) Акрилсодержащие модуляторы ядерного транспорта и их применение
KR20250117821A (ko) Hdac 억제제 및 이의 용도
KR20250005323A (ko) 신경병증을 치료하는 방법
WO2021257669A1 (en) Synthesis of substituted arylmethylureas, analogues, and crystalline forms thereof and methods of using same
WO2020046941A1 (en) Crystalline forms of substituted dihydroindene-4-carboxamide compounds and methods of preparing and using same
AU2004202030A1 (en) New quaternary ammonium compounds, a process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140123